Cereton solution 250mg/ml 4ml ampoules, 3pcs

Composition

>

1 ml contains:

Active ingredient:

glycerylphosphorylcholine hydrate 250 mg,

excipients:

water for injection

Pharmacological action

Pharmacodynamics

Cereton provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation.

Increases the linear velocity of blood flow on the side of traumatic brain damage, contributes to the normalization of spatiotemporal characteristics: spontaneous bioelectric activity of the brain, regression of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral responses of patients with vascular diseases of the brain (dyscirculatory encephalopathy and residual phenomena of cerebral circulatory disorders). It stimulates the dose-dependent release of acetylcholine under physiological conditions, improves synaptic transmission, and receptor function. It does not affect the reproductive cycle and has no teratogenic, mutagenic effect.

It has a preventive and corrective effect on pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes: it participates in the synthesis of phosphatidylcholine (membrane phospholipid), improves the plasticity of neuronal membranes.

Pharmacokinetics

When taken parenterally (10 mg/kg), Ceretone mainly accumulates in the brain, lungs, and liver. Absorption – 88%, easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45% of that in plasma).85% of the drug is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Indications

Acute and recovery periods of severe TBI and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;

Use during pregnancy and lactation

It is contraindicated during pregnancy and lactation.

Contraindications

• pregnancy; breast-feeding period;
• children under 18 years of age (due to lack of data).
• hypersensitivity to the drug;
• acute stage of hemorrhagic stroke;

Side effects

Nausea may occur (mainly as a result of dopaminergic activation), in this case, the dose of the drug is reduced.

From the digestive system: constipation, diarrhea, dryness of the oral mucosa, pharyngitis.

Nervous system disorders: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, convulsions, dizziness.

Skin disorders: rash, urticaria.

Other: pain at the injection site, increased urination.

Allergic reactions.

Interaction

No significant interaction with other drugs was detected.

How to take, course of use and dosage

In acute conditions, the solution is administered intravenously (slowly) or deeply intramuscularly at 1000 mg (1 ampoule) per day for 10-15 days.

Overdose

Symptoms: nausea may occur.

Treatment: symptomatic therapy.

Special instructions

Ceretone does not affect the speed of psychomotor reactions.

Form of production

Solution for intravenous and intramuscular use

Storage conditions

In a dark place, at a temperature not exceeding 25 °C

Shelf life

5 years

Active ingredient

Choline alfoscerate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion